Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: The Business Research Company | PRODUCT CODE: 1435323

Cover Image

PUBLISHER: The Business Research Company | PRODUCT CODE: 1435323

Colorectal Cancer Drugs Global Market Report 2024

Published: Pre-Order
PAGES: 175 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
PDF (Single User License)
USD 5000
PDF (Site License)
USD 7500
PDF (Enterprise License)
USD 10000

Add to Cart

Colorectal cancer (CRC) or bowel cancer is a form of cancer that affects the large intestine and the rectum. Depending on their origin, these cancers are referred to as either colon tumors or rectal cancer.

The main types of drugs used for colorectal cancer treatment include vascular endothelial growth factor (VEGF) inhibitors, epidermal growth factor receptor (EGFR) inhibitors, programmed cell death protein 1/PD1 ligand 1 (PD1/PDL1) inhibitors, BRAF or MEK inhibitors, tyrosine kinase (TKI) inhibitors, and immunomodulators. Vascular endothelial growth factor (VEGF) inhibitors are drugs that block VEGF and VEGFR activity. The different classes of drugs include immunotherapy, chemotherapy, and others, and these medications are typically dispensed through hospital pharmacies, retail pharmacies, and other distribution channels.

The colorectal cancer drugs market research report is one of a series of new reports from The Business Research Company that provides colorectal cancer drugs market statistics, including colorectal cancer drugs industry global market size, regional shares, competitors with a colorectal cancer drugs market share, detailed colorectal cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the colorectal cancer drugs industry. This colorectal cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The colorectal cancer drugs market size has grown strongly in recent years. It will grow from $19.51 billion in 2023 to $20.74 billion in 2024 at a compound annual growth rate (CAGR) of 6.3%. The growth observed in the historical period can be attributed to factors such as the integration of multimodal approaches, the introduction of chemotherapy, advancements in surgical techniques, the emergence of targeted therapies, and the contributions from clinical trials and research efforts.

The colorectal cancer drugs market size is expected to see strong growth in the next few years. It will grow to $26.39 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The anticipated growth in the forecast period can be attributed to the rise in personalized treatment approaches, the adoption of patient-centric care models, the expansion of targeted therapies, increased adoption of combination therapies, and the acceleration of regulatory processes. Major trends expected in the forecast period include advancements in immunotherapy, the evolution of precision medicine, the exploration and application of combination therapies, research and utilization of biomarkers, and innovations in clinical trials.

The anticipated surge in demand for personalized medicines is poised to drive the growth of the colorectal cancer drugs market. Personalized medicine, also referred to as precision medicine, adopts an approach that considers individual variations in genes, environments, and lifestyles for medical treatment. This approach is revolutionizing the treatment of colorectal cancer (CRC), providing more tailored and effective care. As research and drug development align with specific genetic and molecular profiles, the colorectal cancer drugs market is expected to grow. The availability of over 75,000 genetic testing products and 300 personalized medicines, as reported in October 2022 by STAT, underscores the increasing demand for personalized medicine, contributing to the market's growth.

The colorectal cancer drugs market is also expected to witness growth due to the escalating number of clinical trials. Clinical trials, involving human volunteers, evaluate the safety and efficacy of various medical treatments, including drugs designed for colorectal cancer treatment. These trials play a crucial role in identifying novel therapies that can enhance patient outcomes, potentially introducing new drugs to the market. The substantial increase in the number of clinical trials, with over 452,000 registered studies and more than 64,000 actively seeking participants, as reported by Xtalks in May 2023, indicates a significant rise compared to early 2021. This surge in clinical trials is contributing to the growth of the colorectal cancer drugs market.

The use of biologics and targeted therapies poses a restraint on the colorectal cancer drugs market. Biologic therapy harnesses the body's immune system to combat cancer, potentially reducing immune power, while targeted therapies block cancer growth and spread. Despite their advantages, such as specificity to cancer cells and efficacy in advanced stages, these therapies may negatively impact the market by affecting the growth of conventional chemical drugs. The evolving landscape of targeted therapies, including hormone therapies, gene expression modulators, apoptosis inducers, and immunotherapies, signifies a shift in colorectal cancer treatment.

Major companies in the colorectal cancer drugs market are focused on gaining FDA approvals for new drugs to enhance profitability. An example is LONSURF (trifluridine/tipiracil), an oral prescription medication approved by the FDA for treating specific cancers such as colon, rectal, and stomach cancer that has metastasized. Taiho Pharmaceutical Co. Ltd. announced FDA approval for LONSURF in combination with bevacizumab for treating metastatic colorectal cancer in August 2023. The combination significantly increased overall and progression-free survival compared to LONSURF alone.

In October 2023, the Bristol-Myers Squibb Company acquired Mirati Therapeutics Inc for $5.8 billion. This strategic move aimed to add KRAZATI, a prominent lung cancer drug, to Bristol Myers Squibb's commercial portfolio, enhancing and diversifying its oncology offerings. The acquisition aligns with Bristol-Myers Squibb's mission to uncover scientific advancements that promise a life free from cancer. Mirati Therapeutics Inc., a US-based biotech company, contributes valuable therapies to Bristol-Myers Squibb's efforts in the field of oncology.

Major companies operating in the colorectal cancer drugs market report are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Danaher Corporation, Eli Lilly and Company, Amgen Inc., Siemens Healthineers AG, Astellas Pharma Inc., Servier Laboratories, Eisai Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Ipsen SA, Taiho Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Metabiomics Corporation, Randox Laboratories, Taiho Oncology Inc., EDP Biotech Corporation, Genomic Tree Inc., Ono Pharmaceutical Co. Ltd., Epigenomics AG, Daiichi Sankyo Company Limited, Otsuka Pharmaceutical Co. Ltd., Mundipharma International Limited, Teva Pharmaceutical Industries Ltd., Biogen Inc., Gilead Sciences Inc., Johnson & Johnson Services Inc., Spectrum Pharmaceuticals Inc., Exelixis Inc., Seattle Genetics Inc., Incyte Corporation, Clovis Oncology Inc., Karyopharm Therapeutics Inc.

North America was the largest region in the colorectal cancer drugs market in 2023. The Middle East is expected to be the fastest-growing region in the global colorectal cancer drugs market share during the forecast period. The regions covered in the colorectal cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the colorectal cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The colorectal cancer drugs market consists of sales of avastin, bevacizumab, and camptosar. Values in the colorectal cancer drugs market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Colorectal Cancer Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on colorectal cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for colorectal cancer drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The colorectal cancer drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Type: Vascular Endothelial Growth Factor (VEGF) Inhibitors; Epidermal Growth Factor Receptor (EGFR) Inhibitors; Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors; BRAF or MEK Inhibitors; Tyrosine Kinase (TKI) Inhibitors; Immunomodulators
  • 2) By Class: Immunotherapy; Chemotherapy; Other Classes
  • 3) By Distribution Channels: Hospitals Pharmacies; Retail Pharmacies; Other Distribution Channels
  • Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG; Novartis AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.
Product Code: r15037

Table of Contents

1. Executive Summary

2. Colorectal Cancer Drugs Market Characteristics

3. Colorectal Cancer Drugs Market Trends And Strategies

4. Colorectal Cancer Drugs Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Colorectal Cancer Drugs Market Size and Growth

  • 5.1. Global Colorectal Cancer Drugs Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Colorectal Cancer Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Colorectal Cancer Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Colorectal Cancer Drugs Market Segmentation

  • 6.1. Global Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Vascular Endothelial Growth Factor (VEGF) Inhibitors
  • Epidermal Growth Factor Receptor (EGFR) Inhibitors
  • Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors
  • BRAF or MEK Inhibitors
  • Tyrosine Kinase (TKI) Inhibitors
  • Immunomodulators
  • 6.2. Global Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Immunotherapy
  • Chemotherapy
  • Other Classes
  • 6.3. Global Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Other Distribution Channels

7. Colorectal Cancer Drugs Market Regional And Country Analysis

  • 7.1. Global Colorectal Cancer Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Colorectal Cancer Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Colorectal Cancer Drugs Market

  • 8.1. Asia-Pacific Colorectal Cancer Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Colorectal Cancer Drugs Market

  • 9.1. China Colorectal Cancer Drugs Market Overview
  • 9.2. China Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Colorectal Cancer Drugs Market

  • 10.1. India Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Colorectal Cancer Drugs Market

  • 11.1. Japan Colorectal Cancer Drugs Market Overview
  • 11.2. Japan Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Colorectal Cancer Drugs Market

  • 12.1. Australia Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Colorectal Cancer Drugs Market

  • 13.1. Indonesia Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Colorectal Cancer Drugs Market

  • 14.1. South Korea Colorectal Cancer Drugs Market Overview
  • 14.2. South Korea Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Colorectal Cancer Drugs Market

  • 15.1. Western Europe Colorectal Cancer Drugs Market Overview
  • 15.2. Western Europe Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Colorectal Cancer Drugs Market

  • 16.1. UK Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Colorectal Cancer Drugs Market

  • 17.1. Germany Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Colorectal Cancer Drugs Market

  • 18.1. France Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Colorectal Cancer Drugs Market

  • 19.1. Italy Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Colorectal Cancer Drugs Market

  • 20.1. Spain Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Colorectal Cancer Drugs Market

  • 21.1. Eastern Europe Colorectal Cancer Drugs Market Overview
  • 21.2. Eastern Europe Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Colorectal Cancer Drugs Market

  • 22.1. Russia Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Colorectal Cancer Drugs Market

  • 23.1. North America Colorectal Cancer Drugs Market Overview
  • 23.2. North America Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Colorectal Cancer Drugs Market

  • 24.1. USA Colorectal Cancer Drugs Market Overview
  • 24.2. USA Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Colorectal Cancer Drugs Market

  • 25.1. Canada Colorectal Cancer Drugs Market Overview
  • 25.2. Canada Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Colorectal Cancer Drugs Market

  • 26.1. South America Colorectal Cancer Drugs Market Overview
  • 26.2. South America Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Colorectal Cancer Drugs Market

  • 27.1. Brazil Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Colorectal Cancer Drugs Market

  • 28.1. Middle East Colorectal Cancer Drugs Market Overview
  • 28.2. Middle East Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Colorectal Cancer Drugs Market

  • 29.1. Africa Colorectal Cancer Drugs Market Overview
  • 29.2. Africa Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Colorectal Cancer Drugs Market Competitive Landscape And Company Profiles

  • 30.1. Colorectal Cancer Drugs Market Competitive Landscape
  • 30.2. Colorectal Cancer Drugs Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Merck & Co. Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. AbbVie Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Bayer AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Novartis AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Colorectal Cancer Drugs Market Other Major And Innovative Companies

  • 31.1. Sanofi SA
  • 31.2. Bristol-Myers Squibb Company
  • 31.3. AstraZeneca plc
  • 31.4. Abbott Laboratories
  • 31.5. GlaxoSmithKline plc
  • 31.6. Takeda Pharmaceutical Company Limited
  • 31.7. F. Hoffmann-La Roche Ltd.
  • 31.8. Danaher Corporation
  • 31.9. Eli Lilly and Company
  • 31.10. Amgen Inc.
  • 31.11. Siemens Healthineers AG
  • 31.12. Astellas Pharma Inc.
  • 31.13. Servier Laboratories
  • 31.14. Eisai Co. Ltd.
  • 31.15. Sumitomo Dainippon Pharma Co. Ltd.

32. Global Colorectal Cancer Drugs Market Competitive Benchmarking

33. Global Colorectal Cancer Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Colorectal Cancer Drugs Market

35. Colorectal Cancer Drugs Market Future Outlook and Potential Analysis

  • 35.1 Colorectal Cancer Drugs Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Colorectal Cancer Drugs Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Colorectal Cancer Drugs Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!